Alagebrium chloride, a novel advanced glycation end-product cross linkage breaker, inhibits neointimal proliferation in a diabetic rat carotid balloon injury model

Jin Bae Kim, Byeong Wook Song, Sungha Park, Ki Chul Hwang, Bong Soo Cha, Yangsoo Jang, Hyun Chul Lee, Moon Hyoung Lee

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background and Objectives: Vascular perturbation induced by advanced glycation end-products (AGEs) leads to progression of atherosclerosis, plaque instability, and vascular inflammation, which results in a higher risk of neointimal proliferation. Here we investigated the inhibitory effect of alagebrium chloride (ALT-711), a breaker of AGE-based cross links, on neointimal proliferation in a carotid artery balloon injury model in diabetic rats induced by streptozotocin (STZ). Materials and Methods: Rat aortic vascular smooth muscle cells (RASMCs) were treated with 1-100 μM of alagebrium added 24 hours before the addition of AGEs. This in vivo study was done using 8-week-old male rats that were injected intraperitoneally with 80 mg/kg STZ. Sixteen weeks later, the diabetic rats were treated with 10 mg/kg alagebrium for 4 weeks, after which carotid artery balloon injury was induced. After 4 weeks, the animals were sacrificed for histological analysis. Results: Proliferation of RASMCs was significandy inhibited in alagebrium-treated cells. Alagebrium dose-dependently inhibited AGE-mediated formation of reactive oxygen species (ROS), extracellular signal-regulated kinase phosphorylation, and cyclooxygenase-2 expression. The cellular mechanisms of AGE-induced connective tissue and extracellular matrix expression were decreased in the alagebrium-treated group. This in vivo study shows that expression of AGE receptors and neointima hyperplasia are significandy suppressed in balloon-injured rats treated with alagebrium. Conclusion: Alagebrium treatment in diabetic rats significantly inhibits neointimal hyperplasia after carotid balloon injury due to its inhibition of intracellular ROS synthesis, which results in inhibition of RASMCs proliferation.

Original languageEnglish
Pages (from-to)520-526
Number of pages7
JournalKorean Circulation Journal
Volume40
Issue number10
DOIs
Publication statusPublished - 2010 Oct 1

Fingerprint

Advanced Glycosylation End Products
Chlorides
Wounds and Injuries
Vascular Smooth Muscle
Carotid Artery Injuries
Smooth Muscle Myocytes
Streptozocin
Hyperplasia
Blood Vessels
Reactive Oxygen Species
alagebrium
Neointima
Extracellular Signal-Regulated MAP Kinases
Cyclooxygenase 2
Connective Tissue
Extracellular Matrix
Atherosclerosis
Phosphorylation
Cell Proliferation
Inflammation

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Kim, Jin Bae ; Song, Byeong Wook ; Park, Sungha ; Hwang, Ki Chul ; Cha, Bong Soo ; Jang, Yangsoo ; Lee, Hyun Chul ; Lee, Moon Hyoung. / Alagebrium chloride, a novel advanced glycation end-product cross linkage breaker, inhibits neointimal proliferation in a diabetic rat carotid balloon injury model. In: Korean Circulation Journal. 2010 ; Vol. 40, No. 10. pp. 520-526.
@article{ac2555b8fd2f4395b74a435eaf6644f0,
title = "Alagebrium chloride, a novel advanced glycation end-product cross linkage breaker, inhibits neointimal proliferation in a diabetic rat carotid balloon injury model",
abstract = "Background and Objectives: Vascular perturbation induced by advanced glycation end-products (AGEs) leads to progression of atherosclerosis, plaque instability, and vascular inflammation, which results in a higher risk of neointimal proliferation. Here we investigated the inhibitory effect of alagebrium chloride (ALT-711), a breaker of AGE-based cross links, on neointimal proliferation in a carotid artery balloon injury model in diabetic rats induced by streptozotocin (STZ). Materials and Methods: Rat aortic vascular smooth muscle cells (RASMCs) were treated with 1-100 μM of alagebrium added 24 hours before the addition of AGEs. This in vivo study was done using 8-week-old male rats that were injected intraperitoneally with 80 mg/kg STZ. Sixteen weeks later, the diabetic rats were treated with 10 mg/kg alagebrium for 4 weeks, after which carotid artery balloon injury was induced. After 4 weeks, the animals were sacrificed for histological analysis. Results: Proliferation of RASMCs was significandy inhibited in alagebrium-treated cells. Alagebrium dose-dependently inhibited AGE-mediated formation of reactive oxygen species (ROS), extracellular signal-regulated kinase phosphorylation, and cyclooxygenase-2 expression. The cellular mechanisms of AGE-induced connective tissue and extracellular matrix expression were decreased in the alagebrium-treated group. This in vivo study shows that expression of AGE receptors and neointima hyperplasia are significandy suppressed in balloon-injured rats treated with alagebrium. Conclusion: Alagebrium treatment in diabetic rats significantly inhibits neointimal hyperplasia after carotid balloon injury due to its inhibition of intracellular ROS synthesis, which results in inhibition of RASMCs proliferation.",
author = "Kim, {Jin Bae} and Song, {Byeong Wook} and Sungha Park and Hwang, {Ki Chul} and Cha, {Bong Soo} and Yangsoo Jang and Lee, {Hyun Chul} and Lee, {Moon Hyoung}",
year = "2010",
month = "10",
day = "1",
doi = "10.4070/kcj.2010.40.10.520",
language = "English",
volume = "40",
pages = "520--526",
journal = "Korean Circulation Journal",
issn = "1738-5520",
publisher = "Korean Society of Circulation",
number = "10",

}

Alagebrium chloride, a novel advanced glycation end-product cross linkage breaker, inhibits neointimal proliferation in a diabetic rat carotid balloon injury model. / Kim, Jin Bae; Song, Byeong Wook; Park, Sungha; Hwang, Ki Chul; Cha, Bong Soo; Jang, Yangsoo; Lee, Hyun Chul; Lee, Moon Hyoung.

In: Korean Circulation Journal, Vol. 40, No. 10, 01.10.2010, p. 520-526.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Alagebrium chloride, a novel advanced glycation end-product cross linkage breaker, inhibits neointimal proliferation in a diabetic rat carotid balloon injury model

AU - Kim, Jin Bae

AU - Song, Byeong Wook

AU - Park, Sungha

AU - Hwang, Ki Chul

AU - Cha, Bong Soo

AU - Jang, Yangsoo

AU - Lee, Hyun Chul

AU - Lee, Moon Hyoung

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Background and Objectives: Vascular perturbation induced by advanced glycation end-products (AGEs) leads to progression of atherosclerosis, plaque instability, and vascular inflammation, which results in a higher risk of neointimal proliferation. Here we investigated the inhibitory effect of alagebrium chloride (ALT-711), a breaker of AGE-based cross links, on neointimal proliferation in a carotid artery balloon injury model in diabetic rats induced by streptozotocin (STZ). Materials and Methods: Rat aortic vascular smooth muscle cells (RASMCs) were treated with 1-100 μM of alagebrium added 24 hours before the addition of AGEs. This in vivo study was done using 8-week-old male rats that were injected intraperitoneally with 80 mg/kg STZ. Sixteen weeks later, the diabetic rats were treated with 10 mg/kg alagebrium for 4 weeks, after which carotid artery balloon injury was induced. After 4 weeks, the animals were sacrificed for histological analysis. Results: Proliferation of RASMCs was significandy inhibited in alagebrium-treated cells. Alagebrium dose-dependently inhibited AGE-mediated formation of reactive oxygen species (ROS), extracellular signal-regulated kinase phosphorylation, and cyclooxygenase-2 expression. The cellular mechanisms of AGE-induced connective tissue and extracellular matrix expression were decreased in the alagebrium-treated group. This in vivo study shows that expression of AGE receptors and neointima hyperplasia are significandy suppressed in balloon-injured rats treated with alagebrium. Conclusion: Alagebrium treatment in diabetic rats significantly inhibits neointimal hyperplasia after carotid balloon injury due to its inhibition of intracellular ROS synthesis, which results in inhibition of RASMCs proliferation.

AB - Background and Objectives: Vascular perturbation induced by advanced glycation end-products (AGEs) leads to progression of atherosclerosis, plaque instability, and vascular inflammation, which results in a higher risk of neointimal proliferation. Here we investigated the inhibitory effect of alagebrium chloride (ALT-711), a breaker of AGE-based cross links, on neointimal proliferation in a carotid artery balloon injury model in diabetic rats induced by streptozotocin (STZ). Materials and Methods: Rat aortic vascular smooth muscle cells (RASMCs) were treated with 1-100 μM of alagebrium added 24 hours before the addition of AGEs. This in vivo study was done using 8-week-old male rats that were injected intraperitoneally with 80 mg/kg STZ. Sixteen weeks later, the diabetic rats were treated with 10 mg/kg alagebrium for 4 weeks, after which carotid artery balloon injury was induced. After 4 weeks, the animals were sacrificed for histological analysis. Results: Proliferation of RASMCs was significandy inhibited in alagebrium-treated cells. Alagebrium dose-dependently inhibited AGE-mediated formation of reactive oxygen species (ROS), extracellular signal-regulated kinase phosphorylation, and cyclooxygenase-2 expression. The cellular mechanisms of AGE-induced connective tissue and extracellular matrix expression were decreased in the alagebrium-treated group. This in vivo study shows that expression of AGE receptors and neointima hyperplasia are significandy suppressed in balloon-injured rats treated with alagebrium. Conclusion: Alagebrium treatment in diabetic rats significantly inhibits neointimal hyperplasia after carotid balloon injury due to its inhibition of intracellular ROS synthesis, which results in inhibition of RASMCs proliferation.

UR - http://www.scopus.com/inward/record.url?scp=78649411753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649411753&partnerID=8YFLogxK

U2 - 10.4070/kcj.2010.40.10.520

DO - 10.4070/kcj.2010.40.10.520

M3 - Article

C2 - 21088756

AN - SCOPUS:78649411753

VL - 40

SP - 520

EP - 526

JO - Korean Circulation Journal

JF - Korean Circulation Journal

SN - 1738-5520

IS - 10

ER -